Fri, Jan 17, 2020 - Page 2 News List

Doctors urge care to avoid relapse of hepatitis B

By Dennis Xie  /  Staff writer, with CNA

National Taiwan University Hospital doctors hold a news conference in Taipei yesterday, cautioning the public about the seriousness of chronic hepatitis B.

Photo: CNA

The National Health Insurance (NHI) covers only an average of three years of medication fees for people with hepatitis B, highlighting the need for people to closely monitor their condition after the cessation of drugs to prevent a relapse, National Taiwan University Hospital (NTUH) doctors said yesterday.

Chronic hepatitis B is a major health problem in Taiwan, with an estimated 2 million hepatitis B carriers, among whom 20 percent need medication, NTUH Gastroenterology Division attending physician Su Tung-hung (蘇東弘) told a news conference in Taipei.

Although antiviral medications are covered by the NHI, there are requirements for eligibility, and people who no longer meet those requirements, but still need the medication, have to pay for the drugs themselves, he said.

The Asian Pacific Association for the Study of the Liver advises that if virus suppression is proved to be effective over the long term, discontinuing antiviral medications could enhance the possibility of a functional care, meaning the absence of the hepatitis B surface antigen and the presence of the surface antibody in the serum, Su said.

This type of patient tends to have a good prognosis, meaning a better chance of recovery and also a lower risk of liver cancer, he added.

The NTUH Hepatitis Research Center conducted a study tracking people with chronic hepatitis B who had taken medications for three years on average before ceasing medication, and found that one year into the cessation, about 60 percent of the cases were detected with a viral load exceeding 2000 IU/mL, while another 30 percent exhibited symptoms of a virological and clinical relapse.

Unlike hepatitis C, hepatitis B cannot be cured, and the virus affecting liver cells could replicate easily once a patient stops taking antiviral medications, resulting in a high relapse rate of the disease, he said.

The type of antiviral medication is associated with the speed and form of a relapse after drug discontinuance, NTUH Hepatitis Research Center director Liu Chun-jen (劉俊人) said.

While a virological or clinical relapse could occur as early as one month after drug cessation, most occur between three and nine months, and a much lower relapse rate is observed after one year, Liu said.

The research team also found that the surface antibody detected before and one month into the cessation, as well as different DNA sequences, could be indices to predict the virological and clinical relapse rates of hepatitis B, Liu said.

Patients should undertake liver function and supersonic examinations to monitor their condition every month in the first three months of drug cessation, and every three months thereafter, Su said.

Even though the relapse rate is low when no signs are shown for a year following the drug cessation, a regular checkup every six months is still needed, he said.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top